Physician profile
Otis Bennett Walton
NPI 1942591839
$310,572.99
in general payments reported to CMS, 2019-2025
26 companies · $955 in 2025
The $955 reported for 2025 was more than what 76% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $6,460 · 2020: $8,199 · 2021: $49K · 2022: $70K · 2023: $57K · 2024: $119K · 2025: $955.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $116K · Consulting Fee: $53K · Food and Beverage: $4,409 · Travel and Lodging: $3,397 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $115,909.98 |
| Consulting Fee | $52,853.50 |
| Food and Beverage | $4,408.57 |
| Travel and Lodging | $3,397.01 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $139,362.15 | 2019-2025 | Clareon, Acrysof Iq Panoptix Uv Iol, Acrysof Iq Vivity |
| Rxsight INC | $106,097.30 | 2019-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Lensar, INC. | $28,095.08 | 2022-2023 | Lensar Laser System |
| Carl Zeiss Meditec, INC. | $14,928.86 | 2019-2023 | Artevo 800, Lumera 700 |
| Alcon Research LLC | $13,694.83 | 2022-2024 | |
| Glaukos Corporation | $1,606.76 | 2021-2025 | Kxl System (Not Refurbished), Photrexa Viscous and Photrexa, Photrexa Cross-Linking Kit |
| Omeros Corporation | $1,602.16 | 2019-2020 | |
| Allergan, INC. | $1,232.06 | 2021-2022 | |
| Bausch & Lomb Americas INC. | $706.40 | 2022-2024 | Lotemax Sm, Prolensa, Vyzulta |
| Beaver-Visitec International, INC. | $551.32 | 2022-2023 | |
| Johnson & Johnson Surgical Vision, INC. | $508.07 | 2019-2025 | Veritas Vision System, Catalys System |
| Sun Pharmaceutical Industries INC. | $423.55 | 2019-2023 | Cequa |
| Carl Zeiss Meditec USA, INC. | $409.73 | 2021-2022 | |
| Biotissue Holdings INC. | $391.14 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $153.51 | 2021-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $143.69 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $130.72 | 2019-2021 | |
| Abbvie INC. | $117.72 | 2022-2023 | Durysta |
| Dompe US, INC. | $111.30 | 2024-2025 | Oxervate |
| Johnson & Johnson Vision Care, INC. | $100.55 | 2024 | Acuvue |
| Eyepoint US, INC. | $61.56 | 2019 | |
| Oyster Point Pharma, INC. | $49.57 | 2022 | |
| New World Medical,INC. | $31.35 | 2025 | Streamline, Via360, Clearpath |
| Thea Pharma INC. | $24.01 | 2022 | |
| Sight Sciences, INC. | $22.91 | 2024 | Omni Surgical System |
| Shire North American Group INC | $16.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$3,426.63 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
$82,386.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Otis Walton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.